Skip to main content
Clinical Trials/NL-OMON34971
NL-OMON34971
Completed
Not Applicable

Role of hypercoagulability and hypofibrinolysis in the progression of hepatic fibrosis - Coagulation and Fibrosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
hepatic fibrosis
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
292
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. All participants of the Rotterdam Study (cohorts RS I\-5, RS II\-3 and RS III\-1\).
  • \- 1a. TE values \>12,5 kPa in the absence of steatosis will be considered as presence of advanced fibrosis. TE values \>10,5 kPa in the presence of steatosis will be considered as presence of advanced fibrosis (cases).
  • \- 1b. TE values \< 5 kPa will be considered as absence of fibrosis or presence of mild fibrosis (controls)
  • 2\. Male or female, age \>\=18
  • 3\. All subjects must have provided written informed consent.

Exclusion Criteria

  • a. Subjects with unreliable Fibroscan and/or US\-examination, as evaluated by the executing technician.
  • b. No informed consent
  • c. Subjects with decompensated cirrhosis

Outcomes

Primary Outcomes

Not specified

Similar Trials